Our community narratives are driven by numbers and valuation.
Celon Pharma is betting on two big moves: building a Europe-based supply hub for a fast-growing weight-loss drug class and pushing key mental health programs into late-stage testing. The upside comes with long timelines and trial risk, but success could reshape the company beyond its current generics business.Read more
Nanogroup is building the NanOX system to help more donated kidneys stay usable for longer, aiming to ease a worldwide shortage of transplant organs. Early test results and a planned path to approvals and partnerships suggest a big upside, but it still hinges on proving safety and success in human trials.Read more